Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Gopal YN, et al. Cancer Res. 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8. Cancer Res. 2014. PMID: 25297634 Free PMC article.
Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.
Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW, Mann GJ, Thompson JF, Scolyer RA, Hayward NK. Dutton-Regester K, et al. Among authors: pupo gm. Pigment Cell Melanoma Res. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23. Pigment Cell Melanoma Res. 2013. PMID: 23890154
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, Rizos H. Carlino MS, et al. Among authors: pupo gm. Mol Cancer Ther. 2013 Jul;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3. Mol Cancer Ther. 2013. PMID: 23645591 Clinical Trial.
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P. Tiffen JC, et al. Among authors: pupo gm. Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809. Oncotarget. 2015. PMID: 26304929 Free PMC article.
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients.
Mactier S, Kaufman KL, Wang P, Crossett B, Pupo GM, Kohnke PL, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI. Mactier S, et al. Among authors: pupo gm. Pigment Cell Melanoma Res. 2014 Nov;27(6):1106-16. doi: 10.1111/pcmr.12290. Epub 2014 Aug 14. Pigment Cell Melanoma Res. 2014. PMID: 24995518 Free PMC article.
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA. Parmenter TJ, et al. Among authors: pupo gm. Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27. Cancer Discov. 2014. PMID: 24469106 Free PMC article.
44 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page